Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
The purpose is to investigate anti-tumor effect of ixabepilone in patients with locally
recurrent or metastatic breast cancer (mBC) selected by the Ixabepilone DRP after failure of
an anthracycline and taxanes.